Correlates of protection from dengue in a long-term family cohort in Thailand
Official title: Defining correlates of protection from dengue illness in a long-term cohort study of multigenerational house-holds in Thailand
Funded at Upstate Medical University · NIH-11394407 · Data updated 2026-11-12
This project looks at how children’s early exposure to flaviviruses shapes protection against dengue for future infections in a long-running family cohort in Thailand.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | July 10, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $427,769 |
| NIH project number | 5R01AI175941-04 |
| Project ID | NIH-11394407 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and family members in dengue-endemic regions who are part of the long-term Kamphaeng Phet cohort or similar multigenerational families.
✕Less likely to help
Participants not experiencing dengue or changes in immune status may not directly benefit beyond standard monitoring.
What this research studies
Researchers will study a large multigenerational cohort in Kamphaeng Phet, Thailand, to understand how early exposures to dengue and related viruses influence later antibody responses and disease outcomes. They will measure antibody levels and other immune markers over time, linking them to subsequent dengue infections. The study builds on years of ongoing surveillance and will identify immune signatures that predict protection against multiple dengue serotypes. Findings could guide better vaccines and immune tests for dengue in children and families in endemic regions.
Why it matters
Potential benefit: Identifying immune correlates of protection could improve dengue vaccines and diagnostic tests, ultimately reducing severe dengue in vulnerable kids.
How similar studies have gone: Prior work has shown durable, multi-typic immunity can develop with repeated exposure in endemic areas, supporting this approach.
Where this research is happening
-
Upstate Medical University
Syracuse, United States Active
Researchers
- Principal investigator: Anderson, Kathryn B — Upstate Medical University
- Study coordinator: Anderson, Kathryn B
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.